Brain abscesses in children with cancer.
BACKGROUND
Brain abscesses in pediatric patients are rare events, and the causative organism and prognosis vary with the population under study. Children with cancer seem to be particularly susceptible to the development of brain abscesses because of the immunological changes induced by cancer and its treatment. We reviewed the records of children who developed a brain abscess during treatment of a malignancy to define the clinical characteristics, prognosis, and management of these patients.


METHODS
We performed a retrospective review of the clinical and laboratory characteristics of all cancer patients younger than age 20 years who were admitted to our institution between 1980 and 1996 for a brain abscess.


RESULTS
Twelve children were identified. Cancer diagnoses were brain tumor in two, systemic PNET in two, and leukemia in eight. Six patients had multiple abscesses. Eleven received prior chemotherapy. Abscesses were surgically excised or aspirated in seven, and empiric antibiotics were given to the other five. At surgery, Listeria monocytogenes, Aspergillus fumigatus (3), Fusarium, and Candida lusitanea were cultured. Aspergillus was identified in other locations in four patients. Abscesses were successfully treated in seven patients, two of whom received antibiotics only; five patients (42%) died from infection.


CONCLUSIONS
Mortality is high in this immunosuppressed population, in part due to the preponderance of fungal infection. The finding of very rare organisms suggests that drainage and culture should be performed whenever possible; empiric antibiotics that include an antifungal agent may, on occasion, be successful.
Antunes
N L
NL
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. AntunesN@mskcc.org
Hariharan
S
S
DeAngelis
L M
LM
D000038:Abscess / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001927:Brain Diseases / Q000209:etiology / Q000473:pathology / Q000628:therapy; D001932:Brain Neoplasms / Q000150:complications; D002648:Child; D005260:Female; D006801:Humans; D007938:Leukemia / Q000150:complications; D008297:Male; D009181:Mycoses / Q000188:drug therapy / Q000473:pathology; D009369:Neoplasms / Q000150:complications*; D018241:Neuroectodermal Tumors, Primitive, Peripheral / Q000150:complications; D011379:Prognosis; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents